Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Akalin, Altuna Dr. (2) Berruezo Llacuna, Maria (1) Daumke, Oliver Prof. Dr. (1) Di Virgilio, Michela Prof. Dr. (1) Driesner, Madlen (1) Franke, Vedran Dr. (1) Graf, Robin Dr. (2) Höpken, Uta Elisabeth PD Dr. (1) Hübner, Norbert Prof. Dr. (1) Keller, Lisa (1) Keller, Ulrich Dr. med. (2) Kocks, Christine Dr. (1) Kolesnichenko, Marina Dr. (1) Leutz, Achim Prof. Dr. (1) Mertins, Philipp Dr. (1) Patone, Giannino Dr. (1) Popp, Oliver Dr. (1) Prigione, Alessandro Prof. Dr. (1) Rajewsky, Klaus Prof. Dr. (1) Rehm, Armin Dr. (1) Scheidereit, Claus Prof. Dr. (1) Selbach, Matthias Prof. Dr. (1) Wollert-Wulf, Brigitte (1) (-) Janz, Martin Dr. (10) (-) Mathas, Stephan Dr. (13) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (3) 2004 (3) 2005 (3) 2006 (5) 2007 (4) 2008 (4) 2009 (4) 2010 (3) (-) 2011 (4) 2012 (2) 2013 (3) 2014 (2) (-) 2015 (5) 2016 (3) 2017 (5) 2018 (1) (-) 2019 (2) (-) 2020 (6) 2021 (3) 2022 (7) 2023 (10) 2024 (2) Bioinformatics and Omics Data Science (2) (-) Biology of Malignant Lymphomas (17) Genetics and Genomics of Cardiovascular Diseases (1) Genome Diversification & Integrity (1) Mathematical Modelling of Cellular Processes (1) Mechanism-based Cancer Therapies (2) Microenvironmental Regulation in Autoimmunity and Cancer (2) Proteome Dynamics (1) Proteomics and Molecular Mechanisms of Neurodegenerative Diseases (1) Structural Biology of Membrane-Associated Processes (1) Systems Biology of Gene Regulatory Elements (1) Translational Tumorimmunology (1) 17 Results: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biology of Malignant Lymphomas2011201520192020 Sort: Result score Newest to oldest Oldest to newest June 01, 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz November 01, 2011 / Br J Haematol BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines K. Ullrich K.D. Wurster B. Lamprecht K. Koechert A. Engert B. Doerken M. Janz S. Mathas August 01, 2011 / J Exp Med Genomic loss of the putative tumor suppressor gene E2A in human lymphoma A. Steininger M. Moebs R. Ullmann K. Koechert S. Kreher B. Lamprecht I. Anagnostopoulos M. Hummel J. Richter M. Beyer M. Janz C.D. Klemke H. Stein B. Doerken W. Sterry E. Schrock S. Mathas C. Assaf July 14, 2011 / Oncogene Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells U.M. Fagerli K. Ullrich T. Stuehmer T. Holien K. Koechert R.U. Holt O. Bruland M. Chatterjee H. Nogai G. Lenz J.D. Shaughnessy S. Mathas A. Sundan R.C. Bargou B. Doerken M. Borset M. Janz April 14, 2011 / Oncogene High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas K. Koechert K. Ullrich S. Kreher J.C. Aster M. Kitagawa K. Joehrens I. Anagnostopoulos F. Jundt B. Lamprecht U. Zimber-Strobl H. Stein M. Janz B. Doerken S. Mathas March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas June 01, 2020 / JAMA Oncol Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial P.J. Bröckelmann H. Goergen U. Keller J. Meissner R. Ordemann T.V. Halbsguth S. Sasse M. Sökler A. Kerkhoff S. Mathas A. Hüttmann M. Bormann A. Zimmermann J. Mettler M. Fuchs B. von Tresckow C. Baues A. Rosenwald W. Klapper C. Kobe P. Borchmann A. Engert Pagination Current page 1 Page 2 Next page Next › Last page Last »
April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert
January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz
May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz
November 01, 2011 / Br J Haematol BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines K. Ullrich K.D. Wurster B. Lamprecht K. Koechert A. Engert B. Doerken M. Janz S. Mathas
August 01, 2011 / J Exp Med Genomic loss of the putative tumor suppressor gene E2A in human lymphoma A. Steininger M. Moebs R. Ullmann K. Koechert S. Kreher B. Lamprecht I. Anagnostopoulos M. Hummel J. Richter M. Beyer M. Janz C.D. Klemke H. Stein B. Doerken W. Sterry E. Schrock S. Mathas C. Assaf
July 14, 2011 / Oncogene Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells U.M. Fagerli K. Ullrich T. Stuehmer T. Holien K. Koechert R.U. Holt O. Bruland M. Chatterjee H. Nogai G. Lenz J.D. Shaughnessy S. Mathas A. Sundan R.C. Bargou B. Doerken M. Borset M. Janz
April 14, 2011 / Oncogene High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas K. Koechert K. Ullrich S. Kreher J.C. Aster M. Kitagawa K. Joehrens I. Anagnostopoulos F. Jundt B. Lamprecht U. Zimber-Strobl H. Stein M. Janz B. Doerken S. Mathas
March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas
June 01, 2020 / JAMA Oncol Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial P.J. Bröckelmann H. Goergen U. Keller J. Meissner R. Ordemann T.V. Halbsguth S. Sasse M. Sökler A. Kerkhoff S. Mathas A. Hüttmann M. Bormann A. Zimmermann J. Mettler M. Fuchs B. von Tresckow C. Baues A. Rosenwald W. Klapper C. Kobe P. Borchmann A. Engert